14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today ACRS ranks #15371 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Aclaris Therapeutics Stock Forecast NASDAQ:ACRS

$10.37 (-1.24%)

Volume: 420k

Closed: Jan 26, 2022

Hollow Logo Score: -3.774

Aclaris Therapeutics Stock Forecast

$10.37 (-1.24%)

Volume: 420k

Closed: Jan 26, 2022

Score Hollow Logo -3.774

Aclaris Therapeutics Company Profile

101 Lindenwood Drive

Malvern PA 19355



Industry: Biotechnology

Sector: Healthcare

Aclaris Therapeutics


Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical drugs to address various needs in dermatology. Its lead drug candidate is A-101, a hydrogen peroxide topical solution that has completed three Phase II clinical trials for the treatment of seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101 as a prescription treatment for common warts; and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Malvern, Pennsylvania.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE